---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010548"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2022-07-06T23:59:59+00:00"
generated_at: "2026-06-24T21:01:22.291096+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Passage Bio appoints Dr. Michael Kamarck as Class I director

## Summary
- Dr. Kamarck appointed to board and Governance Committee, effective July 2, 2022.
- He is Chairman of Sanofi Biotech Advisory Council and former CTO at Vir Biotechnology.
- Received options to purchase 48,000 shares vesting over 36 months; cash per director policy.
- Background includes ~30 years leadership at Merck, Wyeth, and Bayer.

## SEC filing metadata
- accession: 0001558370-22-010548
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2022-07-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837022010548/0001558370-22-010548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837022010548/pasg-20220702x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010548
- JSON: https://secwatch.observer/filing/0001558370-22-010548.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010548.txt

## Key facts
- Executive change
  Dr. Michael Kamarck was appointed as Class I director at Passage BIO, Inc..
  - Action: appointed
  - Role: Class I director
  source text: appointed Dr. Michael Kamarck as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837022010548/0001558370-22-010548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.